Equities

Titan Pharmaceuticals Inc

Titan Pharmaceuticals Inc

Actions
  • Price (EUR)0.00
  • Today's Change0.00 / --
  • Shares traded--
  • 1 Year change-100.00%
  • Beta--
Data delayed at least 15 minutes, as of Jan 09 2024 07:20 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Titan Pharmaceuticals Inc had revenues fall -66.97% from 557.00k to 184.00k, though the company grew net income from a loss of 10.21m to a smaller loss of 5.57m.
Gross margin--
Net profit margin-136,525.00%
Operating margin-178,225.00%
Return on assets-211.58%
Return on equity-369.11%
Return on investment-368.99%
More ▼

Cash flow in USDView more

In 2023, Titan Pharmaceuticals Inc increased its cash reserves by 116.18%, or 3.64m. Cash Flow from Financing totalled 10.00m or 5,434.78% of revenues. In addition the company used 7.09m for operations while cash from investing totalled 732.00k.
Cash flow per share-6.63
Price/Cash flow per share--
Book value per share4.37
Tangible book value per share4.37
More ▼

Balance sheet in USDView more

Titan Pharmaceuticals Inc appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio12.22
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.